Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 1Iron Deficiencies 1Carcinoma, Ovarian Epithelial 1Anemia, Iron-Deficiency 1Anemia 1

Interventions

Carboplatin 66Paclitaxel 54pembrolizumab 49Cyclophosphamide 34Cisplatin 28Bevacizumab 26Nivolumab 21Gemcitabine 18fludarabine 17liposomal doxorubicin 15Topotecan 15aldesleukin 13Filgrastim 12olaparib 11Interleukin-2 11Docetaxel 11Peripheral Blood Stem Cell Transplantation 10durvalumab 9Taxes 9Specimen Handling 9Oxaliplatin 8fludarabine phosphate 7epacadostat 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Injections 7rucaparib 6niraparib 6lenvatinib 6cemiplimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Ferric Oxide, Saccharated × Gynecologic × Clear all
NCT03933813 2023-01-05

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

University of Wisconsin, Madison

Phase 1/2 Terminated
9 enrolled
Classical hematologyGynecologic

Carcinoma, Ovarian Epithelial, Iron Deficiencies, Anemia, Ovarian Neoplasms, Anemia, Iron-Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡